These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 19709980)

  • 21. Interferon Alfa-2b or not 2b? Significant differences exist in the decision-making process between melanoma patients who accept or decline high-dose adjuvant interferon Alfa-2b treatment.
    Bramlette TB; Lawson DH; Washington CV; Veledar E; Johns BR; Brisman SF; Abramova L; Chen SC
    Dermatol Surg; 2007 Jan; 33(1):11-6. PubMed ID: 17214673
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neuropsychiatric complications associated with interferon - alpha -2b treatment of malignant melanoma.
    Enudi W; Udolu OJ
    Afr J Psychiatry (Johannesbg); 2009 Aug; 12(3):227-8. PubMed ID: 19750253
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potential drug-drug interaction between interferon alfa-2b and gemfibrozil in a patient with malignant melanoma.
    Wong SF; Jakowatz JG; Taheri R
    Clin Ther; 2005 Dec; 27(12):1942-8. PubMed ID: 16507380
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Psychiatric side effects during adjuvant therapy with interferon-alphain patients with malignant melanoma. Clinical evaluation as well as diagnostic and therapeutic possibilities].
    Schäfer M; Messer T; Wegner U; Schmid-Wendtner MH; Volkenandt M
    Hautarzt; 1999 Sep; 50(9):654-8. PubMed ID: 10501682
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Prevalence of psychiatric disorders in French general practice using the patient health questionnaire: comparison with GP case-recognition and psychotropic medication prescription].
    Norton J; de Roquefeuil G; David M; Boulenger JP; Ritchie K; Mann A
    Encephale; 2009 Dec; 35(6):560-9. PubMed ID: 20004287
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Autoimmunity as a prognostic factor in melanoma patients treated with adjuvant low-dose interferon alpha.
    Satzger I; Meier A; Schenck F; Kapp A; Hauschild A; Gutzmer R
    Int J Cancer; 2007 Dec; 121(11):2562-6. PubMed ID: 17680564
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Delayed wound healing following treatment with low-dose interferon alfa-2b for cutaneous melanoma.
    Ammoury AF; El Sayed F; Bazex J
    Arch Dermatol; 2007 Oct; 143(10):1339-40. PubMed ID: 17938359
    [No Abstract]   [Full Text] [Related]  

  • 28. Management of hypertriglyceridemia in patients receiving interferon for malignant melanoma.
    Wong SF; Jakowatz JG; Taheri R
    Ann Pharmacother; 2004 Oct; 38(10):1655-9. PubMed ID: 15304625
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Depressive symptoms in patients with hepatitis C treated with pegylated interferon alpha therapy: a 24-week prospective study.
    Pavlović Z; Delić D; Marić NP; Vuković O; Jašović-Gašić M
    Psychiatr Danub; 2011 Dec; 23(4):370-7. PubMed ID: 22075738
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early signs of liver failure after low-dose interferon alfa-2b for cutaneous melanoma.
    Ammoury A; El Sayed F; Farah C; Bazex J
    J Am Acad Dermatol; 2008 Mar; 58(3):532-3. PubMed ID: 18280369
    [No Abstract]   [Full Text] [Related]  

  • 31. Factors influencing long-term changes in mental health after interferon-alpha treatment of chronic hepatitis C.
    Schmidt F; Janssen G; Martin G; Lorenz R; Loeschke K; Soyka M; Folwaczny C; Schaefer M
    Aliment Pharmacol Ther; 2009 Nov; 30(10):1049-59. PubMed ID: 19691667
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quality-of-life evaluation in an interferon therapy after radical surgery in cutaneous melanoma patients.
    Rataj D; Jankowiak B; Krajewska-Kułak E; Van Damme-Ostapowicz K; Nowecki ZI; Rutkowski P; Niczyporuk W
    Cancer Nurs; 2005; 28(3):172-8. PubMed ID: 15915059
    [TBL] [Abstract][Full Text] [Related]  

  • 33. De novo depression and anxiety disorders and influence on adherence during peginterferon-alpha-2a and ribavirin treatment in patients with hepatitis C.
    Martín-Santos R; Díez-Quevedo C; Castellví P; Navinés R; Miquel M; Masnou H; Soler A; Ardevol M; García F; Galeras JA; Planas R; Solà R
    Aliment Pharmacol Ther; 2008 Feb; 27(3):257-65. PubMed ID: 17988237
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.
    Hancock BW; Wheatley K; Harris S; Ives N; Harrison G; Horsman JM; Middleton MR; Thatcher N; Lorigan PC; Marsden JR; Burrows L; Gore M
    J Clin Oncol; 2004 Jan; 22(1):53-61. PubMed ID: 14665609
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma.
    Pectasides D; Dafni U; Bafaloukos D; Skarlos D; Polyzos A; Tsoutsos D; Kalofonos H; Fountzilas G; Panagiotou P; Kokkalis G; Papadopoulos O; Castana O; Papadopoulos S; Stavrinidis E; Vourli G; Ioannovich J; Gogas H
    J Clin Oncol; 2009 Feb; 27(6):939-44. PubMed ID: 19139440
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Imiquimod, pegylated interferon-alpha-2b and interleukin-2 in the treatment of cutaneous melanoma metastases].
    Loquai C; Nashan D; Metze D; Beiteke U; Rüping KW; Luger TA; Grabbe S
    Hautarzt; 2004 Feb; 55(2):176-81. PubMed ID: 14968329
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Regulatory T cells and other lymphocyte subpopulations in patients with melanoma developing interferon-induced thyroiditis during high-dose interferon-α2b treatment.
    Soldevila B; Alonso N; Martínez-Arconada MJ; Granada ML; Boada A; Vallejos V; Fraile M; Fernández-Sanmartín MA; Pujol-Borrell R; Puig-Domingo M; Sanmartí A; Martínez-Cáceres EM
    Clin Endocrinol (Oxf); 2013 Apr; 78(4):621-8. PubMed ID: 22957689
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prediction of the depressive effects of interferon alfa therapy by the patient's initial affective state.
    Capuron L; Ravaud A
    N Engl J Med; 1999 Apr; 340(17):1370. PubMed ID: 10223879
    [No Abstract]   [Full Text] [Related]  

  • 39. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions.
    Capuron L; Gumnick JF; Musselman DL; Lawson DH; Reemsnyder A; Nemeroff CB; Miller AH
    Neuropsychopharmacology; 2002 May; 26(5):643-52. PubMed ID: 11927189
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lack of association of indoleamine 2,3-dioxygenase polymorphisms with interferon-alpha-related depression in hepatitis C.
    Galvão-de Almeida A; Quarantini LC; Sampaio AS; Lyra AC; Parise CL; Paraná R; de Oliveira IR; Koenen KC; Miranda-Scippa A; Guindalini C
    Brain Behav Immun; 2011 Oct; 25(7):1491-7. PubMed ID: 21693183
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.